Celgene Corporation announced unaudited condensed consolidated earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported net income of $216.82 million or $0.46 per diluted share on total revenue of $695.14 million compared to net income of $136.81 million or $0.29 per diluted share on total revenue of $592.47 million for the same period a year ago. Operating income was $236.09 million compared to $159.58 million for the same period a year ago. Income before income taxes was $270.70 million compared to $178.87 million for the same period a year ago. On a non-GAAP basis net income was $259.84 million or $0.56 per diluted share compared to net income of $185.87 million or $0.40 per diluted share for the same period a year ago. Non-GAAP operating income increased 30% to $292 million For the nine months, the company reported net income of $522.53 million or $1.12 per diluted share on total revenue of $1,928.86 million compared to net loss of $1,384.39 million or $3.17 per diluted share on total revenue of $1,626.53 million for the same period a year ago. Operating income was $558.82 million compared to $1,329.76 million for the same period a year ago. Income before income taxes was $671.13 million compared to $1,268.25 million for the same period a year ago. On a non-GAAP basis net income was $681.01 million or $1.46 per diluted share compared to net income of $517.86 million or $1.13 per diluted share for the same period a year ago.

Celgene Corporation announced that they will report Q4, 2009 results on January 28, 2010.

Celgene Corporation provided earnings guidance for the full year of 2009. For the year, the company expect non-GAAP diluted earnings per share to be in a range of $2.05 to $2.10. The company is updating REVLIMID product sales guidance to a range of $1.65 billion to $1.7 billion. And The company expect non-GAAP total revenue to be in a range of $2.6 billion to $2.7 billion.